| Responders to clopidogrel (n = 732) | Nonresponders to clopidogrel (n = 289) | P value |
---|---|---|---|
Male, m (%) | 601 (82.1%) | 151 (52.2%) | 0.000 |
Age, y | 59.2 ± 10.3 | 62.9 ± 9.8 | 0.000 |
BMI, kg/m2 | 25.9 ± 3.2 | 25.6 ± 3.2 | 0.207 |
Medical history, n, (%) | |||
 Diabetes mellitus | 247 (33.7%) | 113 (39.1%) | 0.107 |
 Hypertension | 463 (63.3%) | 205 (70.9%) | 0.020 |
 Previous stroke | 74 (10.1%) | 39 (13.5%) | 0.120 |
 Previous myocardial infarction | 55 (7.5%) | 22 (7.6%) | 0.957 |
 Previous CABG | 3 (0.4%) | 5 (1.7%) | 0.045 |
 Previous PCI | 53 (8.7%) | 27 (6.6%) | 0.236 |
Presentations of ACS | Â | Â | 0.496 |
 Unstable angina | 669 (91.4%) | 258 (89.3%) |  |
 Non-STEMI | 32 (4.4%) | 14 (4.8%) |  |
 STEMI | 31 (4.2%) | 17 (5.9%) |  |
Current or previous smoking, n (%) | 440 (60.1%) | 117 (40.5%) | 0.000 |
Baseline laboratory evaluation | |||
 PLT, × 109/L | 210.5 ± 55.2 | 234.4 ± 62.1 | 0.000 |
 TC, mmol/L | 3.8 ± 0.9 | 4.1 ± 1.0 | 0.000 |
 LDL-C, mmol/L | 2.2 ± 0.7 | 2.4 ± 0.8 | 0.001 |
 HDL-C, mmol/L | 1.0 ± 0.2 | 1.1 ± 0.3 | 0.002 |
 TGs, mmol/L | 1.6 ± 1.0 | 1.5 ± 0.9 | 0.590 |
 Creatinine, μmol/L | 72.0 ± 14.8 | 68.1 ± 17.2 | 0.000 |
Major medication administered in hospital | |||
 ARBs, n, (%) | 110 (15.0%) | 40 (13.8%) | 0.630 |
 ACEIs, n, (%) | 161 (22.0%) | 77 (26.2%) | 0.113 |
 β-blockers, n, (%) | 510 (69.7%) | 209 (72.3%) | 0.404 |
 CCBs, n, (%) | 61 (8.3%) | 21 (7.3%) | 0.572 |
 Statins, n, (%) | 715 (97.7%) | 282 (97.6%) | 0.925 |
 PPIs, n, (%) | 369 (50.4%) | 141 (48.8%) | 0.641 |
Glucose indices | |||
 Fasting glucose, mmol/L | 6.2 ± 2.3 | 6.4 ± 2.0 | 0.154 |
 HbA1c, % | 6.5 ± 1.3 | 6.3 ± 1.2 | 0.093 |
 Glycated albumin, % | 15.6 ± 3.4 | 16.6 ± 3.6 | 0.000 |
 HOMA-IR | 2.40 (1.65–3.77) | 2.54 (1.71–3.95) | 0.513 |